EQS-Ad hoc: Kuros Biosciences AG (N)

EQS-Adhoc: Kuros appoints Philippe Saudan as Chief Development Officer

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel Kuros appoints Philippe Saudan as Chief Development Officer

10.08.2016 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR.

---------------------------------------------------------------------------

Kuros appoints Philippe Saudan as Chief Development Officer

Schlieren (Zurich), Switzerland, August 10, 2016 - Kuros Biosciences announced today that Dr. Philippe Saudan has been appointed Chief Development Officer and member of the Executive Board with immediate effect. Dr. Saudan has spent the last 16 years in the pharmaceutical industry and has held different management roles in research and development (R&D). He has considerable experience in R&D and international project management of multidisciplinary programs. In his last position, he served as Chief Scientific Officer of Cytos Biotechnology, where he worked at the interface between pre-clinical research, manufacturing and development of several clinical projects. Since February 2016, Dr. Saudan has been working as Head of Integration of Kuros Biosciences. In this position, he has been closely involved in the different development programs in tissue repair and regeneration. Dr. Saudan holds a PhD in biology?from the University of Lausanne, Switzerland.?

For further information, please contact: Kuros Biosciences Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 harry.welten@kuros.ch

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Information regarding Kuros is available at www.kuros.ch.

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward- looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

End of ad hoc announcement Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=AVTHLQIHUU Document title: Kuros_CDO_160810

---------------------------------------------------------------------------

10.08.2016 News transmitted by Tensid EQS AG. www.eqs.com

---------------------------------------------------------------------------

Language: English Company: Kuros Biosciences AG Wagistrasse 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@kuros.ch Internet: www.kuros.ch ISIN: CH0011025217 Valor: - Listed: Foreign Exchange(s) SIX End of News EQS Group News Service ---------------------------------------------------------------------------

490963 10.08.2016